Triple-negative and HER2-positive are not places where cancer starts — they are results from laboratory tests on the cancer cells. Every breast cancer is tested for three receptors, and the pattern of results becomes a label. HER2-positive means the cells carry an unusual amount of one protein, HER2. Triple-negative means all three tests came back negative: no estrogen receptor, no progesterone receptor, and no extra HER2. The labels sound like opposites, and in a way they are — one is defined by something extra that was found, the other by three things that were not.
Key Takeaways
- Receptors are proteins that can receive signals telling a cell to grow. Breast cancers are routinely tested for three: ER, PR, and HER2.
- HER2-positive means the cells make too much HER2, and medicines designed to target HER2 exist — so this result opens specific treatment categories.
- Triple-negative means none of the three targets was found. It does not mean there are no treatments; it means the plan is built from other approaches.
- These labels sit on top of the type, stage, and grade. A cancer of either label can be ductal or lobular, small or large.
- Receptor results occasionally differ between the original tumor and a later recurrence, which is why retesting is sometimes suggested.
First, What Receptors Are
A receptor is a protein on or inside a cell that works like a docking station. When the matching substance locks on — a hormone, for example — the cell receives a signal, often a signal to grow. Pathologists test breast cancer cells for three receptors because the results help predict which kinds of treatment may be useful:
- ER — the estrogen receptor. If it is found, the cancer is called estrogen-receptor-positive.
- PR — the progesterone receptor, tested alongside ER. Together, ER and PR are the “hormone receptors.”
- HER2 — a protein involved in normal cell growth, which some cancers produce in excess.
A result is reported as positive (the receptor was found in meaningful amounts) or negative (it was not). Our article on ER, PR, and HER2 testing explains how the laboratory reaches those answers, and our pillar guide to types of breast cancer compared shows how receptor labels combine with type names.
What “HER2-Positive” Means
HER2 is a protein that sits on the surface of cells and helps control growth and division. In a HER2-positive cancer, the cells carry far more HER2 than normal, which can drive faster growth. The laboratory usually measures this in two steps: a staining test that scores how much protein is present, and — when that score is in-between — a second test that counts copies of the HER2 gene itself.
The practical importance of this label is that HER2 can be targeted. A category of medicines exists that was designed to aim at HER2 specifically, and those medicines are a central part of the discussion for HER2-positive cancers. Which of them apply, and in what order, depends on the stage and the rest of the report. Our dedicated explainer on HER2-positive breast cancer describes the label and its testing in more depth.
What “Triple-Negative” Means
Triple-negative breast cancer is defined by absence. The estrogen receptor test is negative, the progesterone receptor test is negative, and the HER2 test is negative — three negatives, hence the name. Because the label describes what was not found, it says nothing by itself about where the cancer started: most triple-negative cancers are ductal, but the label can sit on other types too.
The consequence of the three negatives is about targets. Medicines that block hormone receptors cannot help when those receptors are absent, and HER2-targeted medicines need HER2 to aim at. So the plan for triple-negative cancer is built from other categories of treatment, which your team will discuss; for some triple-negative cancers, immunotherapy — treatment that helps the immune system respond to cancer — is also part of that discussion. None of this means options are lacking. It means the reasoning starts from a different place. Our explainer on triple-negative breast cancer walks through the label and its implications carefully.
The Two Labels, Side by Side
| HER2-Positive | Triple-Negative | |
|---|---|---|
| ER result | May be positive or negative | Negative |
| PR result | May be positive or negative | Negative |
| HER2 result | Positive — extra HER2 is present | Negative |
| Defined by | Something extra that was found | Three things that were not found |
| What the label points to in planning | Medicines designed to target HER2 are a central discussion | Plans are built from other treatment categories, since the three usual targets are absent |
| Type and stage | Can be any type, any stage | Can be any type, any stage |
Notice the first two rows: a HER2-positive cancer can also be hormone-receptor-positive — when all three tests are positive, doctors sometimes say “triple-positive.” The two labels in this article overlap in every way except the HER2 result itself.
What the Labels Change — and What They Do Not
The labels change the treatment conversation, because they describe which targets are available. They do not change the rest of the diagnosis: the type name, the size, the lymph node findings, and the grade still carry their own weight for both groups. Two people can share a label and have quite different plans because those other details differ.
A word of caution about comparisons you may come across: group statistics about these labels exist, but they average together people at every stage and age, and they cannot describe your case. If you want published figures, current figures are published by the American Cancer Society (cancer.org) and the National Cancer Institute (cancer.gov). Your own starting point is your report, read with your care team.
Neighbouring Terms You May Hear
Hormone-receptor-positive
When ER, PR, or both are found, the cancer is called hormone-receptor-positive, and hormone-blocking treatment categories enter the discussion. Our guide to hormone-receptor-positive breast cancer explains this, the most common receptor pattern, on its own.
HER2-low
Newer reports sometimes describe a small amount of HER2 — not enough to count as HER2-positive, but not zero — as “HER2-low.” It is a refinement of the negative category, and it can matter for certain treatment discussions. If the term appears on your report, ask your team what it means in your case.
Triple-positive
All three tests positive: ER, PR, and HER2. Both hormone-based and HER2-targeted categories may be discussed. The name is simply shorthand for the full pattern.
Questions to Ask Your Doctor
- What exactly were my ER, PR, and HER2 results — can you show me where they appear on the report?
- Was my HER2 score borderline, and was the second, gene-counting test needed?
- Does my report use the term HER2-low, and does it change anything we discuss?
- How do these results shape the categories of treatment we will talk about?
- Were the tests done on the biopsy sample or on tissue from surgery — and could results differ?
- If the cancer ever returns, would the receptors be tested again?
- Are there clinical trials or additional tests relevant to my receptor pattern that we should discuss?
Frequently Asked Questions
Can a cancer be both triple-negative and HER2-positive?
No — the labels are mutually exclusive by definition, because triple-negative requires a negative HER2 result. Occasionally, different areas of one tumor test differently, and a report may describe mixed findings; in that case your team will explain which result guides planning and why.
Is one label more serious than the other?
Neither label, on its own, decides seriousness. Stage, grade, and the specifics of each case carry at least as much weight, and modern treatment categories exist for both patterns. General comparisons between groups of patients cannot predict an individual outcome — that conversation belongs with your care team, who know your full report.
Does triple-negative mean there are no treatment options?
No. It means three particular targets are absent, so the plan is built from other categories — which can include surgery, radiation, chemotherapy, and, for some cases, immunotherapy. The absence of those three targets narrows the starting list; it does not empty it.
Can receptor results change over time?
Yes, they can. A cancer that returns or spreads occasionally tests differently from the original tumor, which is why doctors sometimes recommend a fresh biopsy of a new site. A changed result is not a sign the first test was wrong — it is new information that can widen or redirect the options discussed.
What does HER2-low mean for me?
It means the cells carry a small amount of HER2 — below the threshold for “positive.” Whether it affects your plan depends on your stage and history, and the category is still evolving in practice. It is worth a direct question to your team if the phrase appears on your report.
Where can I read more about receptor-based groups?
The American Cancer Society explains hormone-receptor and HER2 groupings in plain language, including how the labels are used in planning.
Related Articles
- Types of Breast Cancer Compared — the complete guide to how the types are classified and how receptor labels fit in.
- Triple-Negative Breast Cancer Explained — what the three negative results mean, in depth.
- HER2-Positive Breast Cancer Explained — how HER2 is tested and why the result matters.
- ER, PR, and HER2 Testing Explained — how the laboratory produces the results behind both labels.
- Hormone-Receptor-Positive Breast Cancer Explained — the neighbouring receptor group, for contrast.
This article is for general educational purposes only and is not medical, legal, or financial advice. It does not replace professional care. Talk to your doctor or care team about your own situation. If you think you may have a medical emergency, call 911.